Ilirjana Bajrami and colleagues’ study unveiled a remarkable discovery, revealing synthetic lethality between the inhibition of ROS proto-oncogene 1 (ROS1) and the E-cadherin-deficient breast cancer subtype. This evidence concerns the gene ROS1 and breast cancer.